Cyprus Chooses Implant Sciences' QS-B220 to Meet Upcoming EU ETD Regulations
Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has sold 8 of its QS-B220 desktop explosives trace detectors to two major international airports in Cyprus , Paphos and Larnaca, which will be subject to the upcoming EU ETD regulations.
"The adoption of our QS-B220 by large and small EU countries alike speaks volumes. We believe that these smaller countries invest in technology that has the best reputation, or is seen as a 'sure thing'. We are very proud and gratified to be recognized by Cyprus and other countries, big and small, as the leader in trace detection," stated Dr. Bill McGann , Implant Sciences' CEO.
Global Laser Defense Eyewear Sales Market Report 2016
"Indeed, this series of sales throughout Europe is a true example of a positive cycle for Implant Sciences. We believe that when a well-known airport selects our technology, it can lead to more positive customer reference sites which, in turn, can lead to additional sales for our company," added Dr. Darryl Jones , Implant Sciences' Vice President of Global Sales and Marketing. "Implant Sciences is proud to supply systems all across the EU to support the first EU ETD deadline in September."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Source : Implant Sciences Corporation - view original press release
Mar 29 - 30, 2017 - London, United Kingdom